BioCentury
ARTICLE | Finance

Boehringer deal, clinical milestones support Bridge IPO

Deal with Boehringer, pending first-in-class readouts help Bridge raise $36M in KOSDAQ IPO

December 19, 2019 11:30 PM UTC
Updated on Dec 20, 2019 at 9:44 PM UTC

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs.

The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate first-in-class molecules discovered in Asia resonated with investors as the company raised W42 billion ($35.8 million) through the sale of 700,000 shares at W60,000 per share in an IPO on KOSDAQ that valued the company at W332 billion ($283 million). Shares began trading Friday, falling W5,700 to W54,300...

BCIQ Company Profiles

Bridge Biotherapeutics Inc.